NYSE Listed Company Manual

Ross Acquisition Corp II Receives NYSE Notice Regarding Delayed Form 10-Q Filing

Retrieved on: 
Monday, August 28, 2023
PALM, NYSE Listed Company Manual, ROSS, Rule, File, Form 10-Q, Notice, Form, Security (finance), NYSE, Cryptocurrency

The Notice has no immediate effect on the listing or trading of the Company’s securities.

Key Points: 
  • The Notice has no immediate effect on the listing or trading of the Company’s securities.
  • Under NYSE listing standards, the Company has six months from the due date of the 10-Q, or until February 21, 2024, to file the Form 10-Q.
  • If the NYSE accepts the Company’s request, then the NYSE may grant an additional six months, or until August 21, 2024, to file the Form 10-Q.
  • The Company intends to file the Form 10-Q as soon as practicable to regain compliance with the Rule.

NYSE to Commence Delisting Proceedings Against F45 Training Holdings Inc. (FXLV)

Retrieved on: 
Friday, August 25, 2023
Professional Services, Finance, NYSE Listed Company Manual, Exchange, Bangladesh Securities and Exchange Commission, Committee, New York Stock Exchange, Security (finance), NYSE, Cryptocurrency

The New York Stock Exchange (“NYSE” or “Exchange”) announced today that the staff of NYSE Regulation has determined to commence proceedings to delist the common stock of F45 Training Holdings Inc. (the “Company”) — ticker symbol FXLV — from the NYSE.

Key Points: 
  • The New York Stock Exchange (“NYSE” or “Exchange”) announced today that the staff of NYSE Regulation has determined to commence proceedings to delist the common stock of F45 Training Holdings Inc. (the “Company”) — ticker symbol FXLV — from the NYSE.
  • Trading in the Company’s common stock will be suspended immediately.
  • NYSE Regulation has determined that the Company’s common stock is no longer suitable for listing based on “abnormally low” price levels, pursuant to Section 802.01D of the Listed Company Manual.
  • The NYSE will apply to the Securities and Exchange Commission to delist the Company’s common stock upon completion of all applicable procedures, including any appeal by the Company of the NYSE Regulation staff’s decision.

Magnum Opus Receives New York Stock Exchange Notice Regarding Late Form 10-Q Filing

Retrieved on: 
Friday, August 25, 2023
Opus, NYSE Listed Company Manual, Security (finance), File, NYSE, Magnum opus, Bank statement, Cryptocurrency, Typesetting

Under the NYSE Rules, the Company has six months from the due date of the June 2023 Form 10-Q, or until February 21, 2024 (the "Deadline"), to file the June 2023 Form 10-Q.

Key Points: 
  • Under the NYSE Rules, the Company has six months from the due date of the June 2023 Form 10-Q, or until February 21, 2024 (the "Deadline"), to file the June 2023 Form 10-Q.
  • The Company can regain compliance with the NYSE Rules at any time prior to the Deadline by filing the June 2023 Form 10-Q.
  • The NYSE notice has no immediate effect on the listing or trading of the Company's securities on the NYSE.
  • While the Company is working diligently to complete the June 2023 Form 10-Q and plans to file the June 2023 Form 10-Q as soon as practicable, the exact timing of the filing is uncertain at this moment.

Arcus Biosciences Announces New Employment Inducement Grants

Retrieved on: 
Thursday, August 24, 2023
Biotechnology, Pharmaceutical, Health, Oncology, Cancer, NYSE Listed Company Manual, NYSE, Compensated emancipation, Pharmaceutical industry

Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today announced that the Compensation Committee of the Company’s Board of Directors granted five new employees options to purchase a total of 14,600 shares of the Company’s common stock at an exercise price per share of $23.03, which was the closing price on August 23, 2023, and restricted stock units to acquire a total of 7,300 shares of the Company’s common stock.

Key Points: 
  • Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today announced that the Compensation Committee of the Company’s Board of Directors granted five new employees options to purchase a total of 14,600 shares of the Company’s common stock at an exercise price per share of $23.03, which was the closing price on August 23, 2023, and restricted stock units to acquire a total of 7,300 shares of the Company’s common stock.
  • The equity awards were granted pursuant to the Company’s 2020 Inducement Plan, which was approved by the Company’s Board of Directors in January 2020 pursuant to the “inducement exception” under NYSE Listed Company Manual Rule 303A.08.

NYSE to Commence Delisting Proceedings with Respect to the Warrants of WeWork Inc. (WE WS)

Retrieved on: 
Tuesday, August 22, 2023
Professional Services, Finance, NYSE Listed Company Manual, Exchange, Bangladesh Securities and Exchange Commission, Committee, Warrant, New York Stock Exchange, Security (finance), NYSE

The New York Stock Exchange (“NYSE”, the “Exchange”) announced today that the staff of NYSE Regulation has determined to commence proceedings to delist the warrants of WeWork Inc. (the “Company”), each whole warrant exercisable for one share of Class A common stock (the “Warrants”)— ticker symbol WE WS — from the NYSE.

Key Points: 
  • The New York Stock Exchange (“NYSE”, the “Exchange”) announced today that the staff of NYSE Regulation has determined to commence proceedings to delist the warrants of WeWork Inc. (the “Company”), each whole warrant exercisable for one share of Class A common stock (the “Warrants”)— ticker symbol WE WS — from the NYSE.
  • Trading in the Company’s Warrants will be suspended immediately.
  • Trading in the Company’s Class A common stock — ticker symbol WE — will continue on the NYSE.
  • NYSE Regulation has determined that the Company’s Warrants are no longer suitable for listing based on “abnormally low” price levels, pursuant to Section 802.01D of the Listed Company Manual.

Yelp Announces New Employee Inducement Grants Under NYSE Rule 303A.08

Retrieved on: 
Friday, August 18, 2023
Digital Marketing, Social Media, Internet, Communications, Technology, Apps, Applications, Online Retail, Retail, NYSE Listed Company Manual, Inc., Employment, Professional Football Compensation Committee, Yelp, NYSE, Compensated emancipation, Pharmaceutical industry

Yelp Inc. (NYSE: YELP), the company that connects people with great local businesses, announced that on August 14, 2023, the Compensation Committee of Yelp’s Board of Directors granted inducement restricted stock unit awards covering 13,144 shares of Yelp’s common stock to five new non-executive employees to induce them to accept employment with Yelp.

Key Points: 
  • Yelp Inc. (NYSE: YELP), the company that connects people with great local businesses, announced that on August 14, 2023, the Compensation Committee of Yelp’s Board of Directors granted inducement restricted stock unit awards covering 13,144 shares of Yelp’s common stock to five new non-executive employees to induce them to accept employment with Yelp.
  • Each award was granted under the Yelp Inc. 2023 Inducement Award Plan and vests over a four-year period, subject to continued employment with Yelp through each vesting date.
  • Each award was granted as a material inducement to employment in accordance with the NYSE Listed Company Manual Rule 303A.08.

Phreesia Awards Inducement Grants as Part of its Acquisition of Access eForms

Retrieved on: 
Tuesday, August 15, 2023
Health, Health Technology, Practice Management, Other Health, Health Insurance, Managed Care, NYSE Listed Company Manual, Employment, Pharmaceutical industry, Financial adviser

On July 13, 2023, Phreesia, Inc.’s (“Phreesia”) Board of Directors approved the grant of restricted stock unit awards pursuant to Phreesia’s 2023 Inducement Award Plan (the “Plan”).

Key Points: 
  • On July 13, 2023, Phreesia, Inc.’s (“Phreesia”) Board of Directors approved the grant of restricted stock unit awards pursuant to Phreesia’s 2023 Inducement Award Plan (the “Plan”).
  • On August 15, 2023, Phreesia made grants pursuant to the Plan in an aggregate amount of 12,285 shares of its common stock to 24 new non-executive employees to induce them to join Phreesia.
  • The awards vest annually in equal installments over a four-year period following their grant, subject to continued employment.
  • Each award was granted as a material inducement to employment in accordance with the NYSE Listed Company Manual Rule 303A.08.

UpHealth Announces Second Quarter 2023 Financial Results

Retrieved on: 
Thursday, August 10, 2023
UPH, Note, Employment, International, Table, Integrated care, RSU, Telephone, Asia Innovations Group, Sale, IGI, EBITDA, Behavior, Acquisition, NYSE Listed Company Manual, Webcast, Growth, NYSE, Bank, Video game, Film industry, Cryptocurrency, Risk management, Bookkeeping, Fine chemical, Glocalization, Marketing, Adjustment

Improved 9% to $27.2 million

Key Points: 
  • Improved 9% to $27.2 million
    Closed Strategic Sale of Innovations Group, Inc. for $56.0 million
    DELRAY BEACH, Fla., Aug. 10, 2023 (GLOBE NEWSWIRE) -- UpHealth, Inc. (“UpHealth” or the “Company”) (NYSE: UPH), a global digital health company delivering technology platforms, infrastructure, and services to modernize care delivery and health management, today announced financial results for the second quarter ended June 30, 2023.
  • Given the second quarter results and execution, we are in a position to increase our full year 2023 outlook.
  • There were no revenues in the second quarter of 2023 from Glocal Healthcare Private Limited (“Glocal”), which was deconsolidated as previously reported, compared to $3.6 million of revenue from Glocal for the second quarter of 2022.
  • Net loss attributable to UpHealth was $19.1 million, compared to a net loss attributable to UpHealth for the second quarter of 2022 of $12.4 million.

Arcus Biosciences Announces New Employment Inducement Grants

Retrieved on: 
Wednesday, August 9, 2023
Science, Biotechnology, Research, Pharmaceutical, Oncology, General Health, Health, Clinical Trials, Cancer, NYSE Listed Company Manual, NYSE, Compensated emancipation, Pharmaceutical industry

Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today announced that the Compensation Committee of the Company’s Board of Directors granted 11 new employees options to purchase a total of 35,400 shares of the Company’s common stock at an exercise price per share of $18.44, which was the closing price on August 8, 2023, and restricted stock units to acquire a total of 17,700 shares of the Company’s common stock.

Key Points: 
  • Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today announced that the Compensation Committee of the Company’s Board of Directors granted 11 new employees options to purchase a total of 35,400 shares of the Company’s common stock at an exercise price per share of $18.44, which was the closing price on August 8, 2023, and restricted stock units to acquire a total of 17,700 shares of the Company’s common stock.
  • The equity awards were granted pursuant to the Company’s 2020 Inducement Plan, which was approved by the Company’s Board of Directors in January 2020 pursuant to the “inducement exception” under NYSE Listed Company Manual Rule 303A.08.

"TO BE GLOBAL. - Performance Reward High Class Business to Business Matching Platform."

Retrieved on: 
Wednesday, July 26, 2023
Advertising, Communication, Face, Management consulting, Procurement, NYSE Listed Company Manual, Business, WNS Global Services, Hope, INC, Domestic, Risk, Growth, Future value, Businessperson, Music, Mobile phone, Turn state's evidence

It is a global High-Class Business to Business matching platform.

Key Points: 
  • It is a global High-Class Business to Business matching platform.
  • Able to have a relationship with "High Class Company" of Global.
  • If you would like to grow your business to the global, you must learn business environment of the other country first.
  • That is High Class Business to Business Matching platform of the Global.